The effect of CYP2C19 genetic polymorphism and non-genetic factors on clopidogrel platelets inhibition in East Asian coronary artery disease patients

[Display omitted] •Clopidogrel HTPR is frequent among East Asians, regardless of using high LD.•CYP2C19*2 and obesity are associated with clopidogrel HTPR, however, genotyping doesn't predict HTPR efficiently.•Absence or possession of CYP2C19*2 doesn't make clopidogrel responsiveness or HT...

Full description

Saved in:
Bibliographic Details
Published in:Thrombosis research 2017-10, Vol.158, p.22-24
Main Authors: Amin, Arwa M., Sheau Chin, Lim, Mohamed Noor, Dzul Azri, Mostafa, Hamza, Abdul Kader, Muhamad Ali S.K., Kah Hay, Yuen, Ibrahim, Baharudin
Format: Article
Language:English
Subjects:
Asian Continental Ancestry Group - genetics
Blood Platelets - drug effects
Clopidogrel
Coronary Artery Disease - blood
Coronary Artery Disease - enzymology
Coronary Artery Disease - genetics
Coronary artery disease patients
CYP2C19
Cytochrome P-450 CYP2C19 - genetics
Dual antiplatelet therapy (DAPT)
Female
High on treatment platelets reactivity
Humans
Male
Platelet Aggregation Inhibitors - pharmacology
Polymorphism, Genetic
Ticlopidine - analogs & derivatives
Ticlopidine - pharmacology
VerifyNow
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:[Display omitted] •Clopidogrel HTPR is frequent among East Asians, regardless of using high LD.•CYP2C19*2 and obesity are associated with clopidogrel HTPR, however, genotyping doesn't predict HTPR efficiently.•Absence or possession of CYP2C19*2 doesn't make clopidogrel responsiveness or HTPR certain.•Haemoglobin and haematocrit interfere with the VerifyNow P2Y12 assay PRU value.•VerifyNow P2Y12 assay percentage of inhibition is strongly associated with CYP2C19*2.
ISSN:0049-3848
1879-2472
DOI:10.1016/j.thromres.2017.07.032